Chief Business Officer at EnteroBiotix
Christian Roghi is the Chief Business Officer at EnteroBiotix, a Scottish biopharmaceutical company that is harnessing the human microbiome to develop novel medicinal products that restore health and prevent disease.
Previously, Christian was Head of Business Development at the Quadram Institute (Norwich, UK), a research organisation exploring how food and the gut microbiota are linked to the promotion of health and the prevention of disease. In addition to this main role, Christian was also a Director of the EIT-Food Innovation hub established in Reading.
Christian holds a PhD in Molecular Cell Biology, an Executive MBA and a Diploma in Management Consulting from the Chartered Management Institute.
He spent 19 years in research laboratories in France, Germany, USA and the UK deciphering the molecular mechanisms underlying cancer tumour progression and metastasis. He authored 25 peer-reviewed scientific publications.
Case Study: Intestinal microbiome medicinal product (IMMP): establishing a licensed platform to create novel products
- FMT is the only approved microbiome therapy available to patients. It’s production and manufacturing for human application is highly regulated and its administration is currently for the most part invasive.
- The efficacy of FMT and more standardised IMMP’s for treating chronic diseases associated with microbial imbalances has so far been modest with a much higher variability in patient response.
- Developing oral IMMP assets from minimally manipulated and manipulated intestinal microbiota will support the widespread use of this powerful therapy in a variety of disease indications